<![CDATA[Genmab — Oktober 2024]]>nothing to worry about; according to insidermonkey Genmab is #2 of the '7 Best Revenue Growth Stocks to Buy According to Analysts' !! 😉 https://www.insidermonkey.com/blog/7-best-revenue-growth-stocks-to-buy-according-to-analysts-1362742/5/

]]>https://dev.proinvestor.com/forum/topic/399189/genmab-oktober-2024RSS for NodeSun, 07 Jun 2026 07:07:30 GMTTue, 01 Oct 2024 04:32:46 GMT60<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 21:31:57 GMT]]>
ClinicalTrials.gov

favicon

(clinicaltrials.gov)

]]>https://dev.proinvestor.com/forum/post/7679970https://dev.proinvestor.com/forum/post/7679970Thu, 31 Oct 2024 21:31:57 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 21:30:06 GMT]]>Hexa38 overgået til "active not recruoting" på CT

]]>https://dev.proinvestor.com/forum/post/7679972https://dev.proinvestor.com/forum/post/7679972Thu, 31 Oct 2024 21:30:06 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 21:18:28 GMT]]>🙂

]]>https://dev.proinvestor.com/forum/post/7679967https://dev.proinvestor.com/forum/post/7679967Thu, 31 Oct 2024 21:18:28 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 16:05:26 GMT]]>hey i see i discovered a new emoticon by accident 🙂

]]>https://dev.proinvestor.com/forum/post/7679971https://dev.proinvestor.com/forum/post/7679971Thu, 31 Oct 2024 16:05:26 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 16:03:42 GMT]]>Joke of the week award goes to Bulder :-0

]]>https://dev.proinvestor.com/forum/post/7679966https://dev.proinvestor.com/forum/post/7679966Thu, 31 Oct 2024 16:03:42 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 15:39:36 GMT]]>Gad vide om de forsøger at kører den ned i nul. Længere ned kan vi trods alt ikke komme.

]]>https://dev.proinvestor.com/forum/post/7679964https://dev.proinvestor.com/forum/post/7679964Thu, 31 Oct 2024 15:39:36 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 14:45:00 GMT]]>I Think i’ll volunteer in that trial. So tired of the current Stock Price.

]]>https://dev.proinvestor.com/forum/post/7679965https://dev.proinvestor.com/forum/post/7679965Thu, 31 Oct 2024 14:45:00 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 14:07:33 GMT]]>There are responders in ongoing pilot trial of Daratumumab for ME/CFS. Now researchers are planning a placebo controlled trial https://x.com/TimofejM77894/status/1851978525726679119

]]>https://dev.proinvestor.com/forum/post/7679968https://dev.proinvestor.com/forum/post/7679968Thu, 31 Oct 2024 14:07:33 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 13:35:46 GMT]]>Had it translated, that helped 😉 great result but can’t see any new date for data ? I hope its new or the remaining pts groups’ data will suffer from this subgroup of Japanees doing so well i guess

]]>https://dev.proinvestor.com/forum/post/7679961https://dev.proinvestor.com/forum/post/7679961Thu, 31 Oct 2024 13:35:46 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 13:02:00 GMT]]>Anyway it seems good news as Japan is a big market for cervical cancer. Probably why shares are up so much today.... 😞

]]>https://dev.proinvestor.com/forum/post/7679960https://dev.proinvestor.com/forum/post/7679960Thu, 31 Oct 2024 13:02:00 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:59:09 GMT]]>@14.38 it is definitely a new data set/cut, and specifically on Japanese patients. The question is if an update of the earlier ESMO data ex-Japan would give a similar improvement? Or does it only work for Japanese patients? Or has for example better toxicity management improved results/ allowed patients to stay on the drug longer? Either way, I would like to know

]]>https://dev.proinvestor.com/forum/post/7679962https://dev.proinvestor.com/forum/post/7679962Thu, 31 Oct 2024 12:59:09 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:53:17 GMT]]>det jo den fra august hvor de downgradede til 2050 så old news

]]>https://dev.proinvestor.com/forum/post/7679969https://dev.proinvestor.com/forum/post/7679969Thu, 31 Oct 2024 12:53:17 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:42:05 GMT]]>Og angående aktieprisen så er jeg gået hen og blevet apatisk. Den er lagt i skuffen og så kigger jeg på den når JnJ har taget stilling til optionen. det er under alle omstændigheder en long hold for mig. 🙂

]]>https://dev.proinvestor.com/forum/post/7679959https://dev.proinvestor.com/forum/post/7679959Thu, 31 Oct 2024 12:42:05 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:39:39 GMT]]>but would be nice to see an international news flash comfirming this.

]]>https://dev.proinvestor.com/forum/post/7679956https://dev.proinvestor.com/forum/post/7679956Thu, 31 Oct 2024 12:39:39 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:39:22 GMT]]>Genmab A/S(Neutral; Price Target: Dkr 2,050)
Investment Thesis
We rate Genmab Neutral, noting:
(1.) The significant shareprice upside and downside risk around JNJ’s opt-in decision
on HexabodyCD38 (HBCD38), likely early 2025, where there is both limited clinical data
on which to take a view from a clinical perspective, and where JNJ has also provided very
little commentary on it’s level of interest in the program. We currently model 50% POS of
an opt-in and $5bn peak sales.

]]>https://dev.proinvestor.com/forum/post/7679958https://dev.proinvestor.com/forum/post/7679958Thu, 31 Oct 2024 12:39:22 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:38:45 GMT]]>EL 13:10, yes wired, makes it sund like TV is working better in J pys. But the info that is WAS 11.5 vs 8.5 I guess tells that this just might be a new data cut? and it would cover alle pts and not only J pts. J is used to have J-specific aren't they ? so could be when it's an international trial they make sure to highlight, that it also works in J pts ? my guess

]]>https://dev.proinvestor.com/forum/post/7679957https://dev.proinvestor.com/forum/post/7679957Thu, 31 Oct 2024 12:38:45 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:32:25 GMT]]>POS, eller "Probability of Success" (sandsynligheden for succes)

]]>https://dev.proinvestor.com/forum/post/7679953https://dev.proinvestor.com/forum/post/7679953Thu, 31 Oct 2024 12:32:25 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:30:08 GMT]]>JPM har peaksalg på 5miausd. Den betydelige op- og nedadgående risiko for aktiekursen omkring JNJs opt-in-beslutning
på HexabodyCD38 (HBCD38), sandsynligvis tidligt i 2025, hvor der både er begrænsede kliniske data
som man kan se på fra et klinisk perspektiv, og hvor JNJ også har ydet meget
lidt kommentar til dets niveau af interesse for programmet. Vi modellerer i øjeblikket 50% POS af
en opt-in og $5 mia. topsalg.

]]>https://dev.proinvestor.com/forum/post/7679954https://dev.proinvestor.com/forum/post/7679954Thu, 31 Oct 2024 12:30:08 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:23:19 GMT]]>Med virksomhedens betydelige ressourcer og innovative forskning er det rimeligt at forvente, at der snart vil blive introduceret nye produkter eller teknologier, som kan generere yderligere indtægter gennem licensering. Spændende hvad Jan disker op med i næste uge.

]]>https://dev.proinvestor.com/forum/post/7679952https://dev.proinvestor.com/forum/post/7679952Thu, 31 Oct 2024 12:23:19 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:21:55 GMT]]>Værdiskabende indlicensering er vel en del af Genmabs strategi, og det rejser spørgsmålet: Må der snart være noget i pipelinen, som de kan sælge?

]]>https://dev.proinvestor.com/forum/post/7679955https://dev.proinvestor.com/forum/post/7679955Thu, 31 Oct 2024 12:21:55 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:13:29 GMT]]>Pipeline succes, såsom for GEN1046 eller GEN1042, hvor markedet har lav
forventninger er kurstriggrs når / hvis der kommer nop-notch data. P.t har markedet lav forventning til hele genmabs pipeline

]]>https://dev.proinvestor.com/forum/post/7679963https://dev.proinvestor.com/forum/post/7679963Thu, 31 Oct 2024 12:13:29 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 12:08:00 GMT]]>Man kan vel sige der er indgået aftaler, hvor det er JJ der bestemmer værdien af CD38, ihvertfald inden for MM. Spørgsmålet er så, hvor meget af Genmab's værdi der lige nu er hæftet til en "Opt-In"? Meget værdi er trods alt hældt ud igen...

]]>https://dev.proinvestor.com/forum/post/7679951https://dev.proinvestor.com/forum/post/7679951Thu, 31 Oct 2024 12:08:00 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 11:52:48 GMT]]>Den estimerede 12-måneders OS-rate var 65,5 % (95 % konfidensinterval: 49,9-77,4) i TV-gruppen og 32,3 % (95 % konfidensinterval: 19,3-46,1) i kemoterapigruppen.

]]>https://dev.proinvestor.com/forum/post/7679950https://dev.proinvestor.com/forum/post/7679950Thu, 31 Oct 2024 11:52:48 GMT<![CDATA[Reply to Genmab — Oktober 2024 on Thu, 31 Oct 2024 11:51:36 GMT]]>I en kommentar til disse resultater sagde Dr. Nishio: `` Da tisotumab vedotin viste effekt og en håndterbar sikkerhedsprofil i den japanske befolkning, anbefales det også i Japan til sekundær og tertiær behandling af fremskreden eller tilbagevendende livmoderhalskræft, der er blevet forværret efter kemoterapi. Det vil være effektivt som en næste behandling."

]]>https://dev.proinvestor.com/forum/post/7679948https://dev.proinvestor.com/forum/post/7679948Thu, 31 Oct 2024 11:51:36 GMT